Luchenko VL - Search Results

1

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE. Chakraborty AR, et al. Among authors: luchenko vl. Blood. 2013 May 16;121(20):4115-25. doi: 10.1182/blood-2012-08-449140. Epub 2013 Mar 26. Blood. 2013. PMID: 23532732 Free PMC article.

2

Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.

Luchenko VL, Litman T, Chakraborty AR, Heffner A, Devor C, Wilkerson J, Stein W, Robey RW, Bangiolo L, Levens D, Bates SE. Luchenko VL, et al. Mol Oncol. 2014 Dec;8(8):1379-92. doi: 10.1016/j.molonc.2014.05.001. Epub 2014 May 28. Mol Oncol. 2014. PMID: 24954856 Free PMC article.

3

Histone deacetylase inhibitors: emerging mechanisms of resistance.

Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Z, Bates SE. Robey RW, et al. Mol Pharm. 2011 Dec 5;8(6):2021-31. doi: 10.1021/mp200329f. Epub 2011 Oct 7. Mol Pharm. 2011. PMID: 21899343 Free PMC article. Review.

4

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL. Bates SE, et al. Br J Haematol. 2010 Jan;148(2):256-67. doi: 10.1111/j.1365-2141.2009.07954.x. Epub 2009 Oct 28. Br J Haematol. 2010. PMID: 19874311 Free PMC article. Clinical Trial.

5

Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.

Bahr JC, Robey RW, Luchenko V, Basseville A, Chakraborty AR, Kozlowski H, Pauly GT, Patel P, Schneider JP, Gottesman MM, Bates SE. Bahr JC, et al. Oncotarget. 2016 Oct 25;7(43):69804-69815. doi: 10.18632/oncotarget.12001. Oncotarget. 2016. PMID: 27634878 Free PMC article.

6

Phase I trial of a new schedule of romidepsin in patients with advanced cancers.

Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL. Amiri-Kordestani L, et al. Clin Cancer Res. 2013 Aug 15;19(16):4499-507. doi: 10.1158/1078-0432.CCR-13-0095. Epub 2013 Jun 11. Clin Cancer Res. 2013. PMID: 23757352 Free PMC article. Clinical Trial.

7

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.

Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, Giaccone G, Pommier Y, Bates SE, Varticovski L. Luchenko VL, et al. Cell Cycle. 2011 Sep 15;10(18):3119-28. doi: 10.4161/cc.10.18.17190. Epub 2011 Sep 15. Cell Cycle. 2011. PMID: 21900747 Free PMC article.

8

A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.

Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE. Kelly RJ, et al. Oncologist. 2012;17(4):512. doi: 10.1634/theoncologist.2012-0080. Epub 2012 Mar 13. Oncologist. 2012. PMID: 22416063 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters